This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
EMA Accepts GSK's Filing for Expanded Use of RSV Vaccine Arexvy
by Zacks Equity Research
GSK's regulatory filing for expanded use of RSV vaccine, Arexvy, in adults aged 18 years and older has been accepted for review by the EMA.
GSKNegative Net Change PFENegative Net Change MRNANegative Net Change
biotechs
RHHBY to Advance Parkinson's Disease Drug to Late-Stage Development
by Zacks Equity Research
Roche is set to advance prasinezumab into phase III for early Parkinson's, eyeing potential first-in-class disease-modifying therapy.
NVSNegative Net Change RHHBYNegative Net Change BAYRYNegative Net Change PRTANegative Net Change
biotechnology biotechs medical pharmaceuticals
SRPT Plummets on Second Patient Death After DMD Gene Therapy Infusion
by Zacks Equity Research
Sarepta's shares sink as second Elevidys-linked death triggers safety concerns, dosing halts and trial pauses.
RHHBYNegative Net Change SRPTNegative Net Change AGENNegative Net Change IMCRNegative Net Change
biotechs gene-editing gene-therapy medical pharmaceuticals
BMY Focuses on Label Expansion of Drugs: Will This Revive Growth?
by Ekta Bagri
BMY's banks on label expansion of drugs like Sotyktu and Opdivo to boost sales in the wake of generic competition for legacy drugs.
BMYNegative Net Change MRKNegative Net Change AMGNNegative Net Change
biotechnology biotechs medical pharmaceuticals
NVO Stock up on Plans to Advance Obesity Candidate Amycretin
by Zacks Equity Research
Novo Nordisk stock climbs following the announcement of its plans to advance amycretin, a dual GLP-1/amylin agonist for obesity, to phase III development.
NVSNegative Net Change NVOPositive Net Change LLYNegative Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
BMY Reports Positive Data on Sotyktu From Arthritis Study
by Zacks Equity Research
Bristol Myers' Sotyktu hits key goals in late-stage PsA trial, fueling hopes for expansion amid recent pipeline setbacks.
NVSNegative Net Change BMYNegative Net Change BAYRYNegative Net Change BNTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Novavax's COVID-Flu Combo Shot Shows Strong Immune Response
by Zacks Equity Research
NVAX's COVID-flu combo shot sparks strong immunity in seniors, fueling plans for further late-stage trials.
SNYNegative Net Change PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Insmed Stock Jumps 29% on Encouraging PAH Study Results
by Zacks Equity Research
INSM eyes the next steps as TPIP hits all endpoints in the PAH study, setting the stage for late-stage trials and broader potential in lung disease.
UTHRPositive Net Change INSMPositive Net Change LQDANegative Net Change
biotechs medical
CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock?
by Sundeep Ganoria
CRSP surges 14% on encouraging CTX310 data and growing Casgevy sales, despite early-stage pipeline risks.
VRTXNegative Net Change BEAMNegative Net Change NTLANo Net Change CRSPPositive Net Change
biotechs cancer crispr gene-editing gene-therapy healthcare medical
FDA Places Clinical Hold on Gilead's HIV Studies, Stock Down
by Zacks Equity Research
GILD slides 2.6% after FDA halts trials for HIV candidates, GS-1720 and GS-4182, over safety concerns in patients.
GSKNegative Net Change NVSNegative Net Change GILDNegative Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Merck Secures FDA Nod for New RSV Antibody Enflonsia in Infants
by Zacks Equity Research
MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.
SNYNegative Net Change AZNNegative Net Change PFENegative Net Change MRKNegative Net Change
biotechs medical pharmaceuticals vaccines
Top Cancer Stocks to Supercharge Your 2025 Portfolio
by Kinjel Shah
Pfizer, Novartis and Fate Therapeutics are making bold oncology moves as demand surges for next-gen cancer therapies.
AZNNegative Net Change NVSNegative Net Change BMYNegative Net Change PFENegative Net Change LLYNegative Net Change ABBVNegative Net Change FATENegative Net Change
biotechs cancer pharmaceuticals
Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM
by Zacks Equity Research
ALNY gains approval to expand Amvuttra's label in the EU, boosting its position as the only RNAi therapy for ATTR-CM.
ALNYNegative Net Change BAYRYNegative Net Change LXRXPositive Net Change AMRNPositive Net Change
biotechnology biotechs medical pharmaceuticals
Have Skyrizi and Rinvoq Successfully Saved AbbVie From Humira LoE?
by Sundeep Ganoria
ABBV eyes $24.7 billion from Skyrizi and Rinvoq in 2025 as ex-Humira growth offsets sharp sales drop post-U.S. patent loss.
JNJNegative Net Change LLYNegative Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
Acquisitions, Licensing Deals Take Centerstage in Pharma/Biotech Space
by Ekta Bagri
SNY, BMY, REGN and others ramp up 2025 dealmaking as pharma/biotech giants chase innovation across key growth areas.
REGNNegative Net Change SNYNegative Net Change NVSNegative Net Change BMYNegative Net Change
biotechnology biotechs cell-therapy medical pharmaceuticals
Is Novo Nordisk's Next Generation Obesity Pipeline a Game Changer?
by Zacks Equity Research
NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.
NVOPositive Net Change LLYNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
KURA Stock Rises More Than 15% This Past Week: Here's Why
by Zacks Equity Research
Kura Oncology shares rise this week after the FDA accepts its NDA for ziftomenib, a potential first-in-class treatment for NPM1-mutant AML.
LXRXPositive Net Change AMRNPositive Net Change KURANegative Net Change CMMBNegative Net Change
biotechs
TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy
by Zacks Equity Research
Tempest jumps after EMA grants orphan drug status to its liver cancer candidate, amezalpat, based on positive study data.
RHHBYNegative Net Change LXRXPositive Net Change CMMBNegative Net Change TPSTNegative Net Change
biotechs
ADMA Stock Gains 17% in Three Months: Buy, Sell or Hold?
by Ekta Bagri
ADMA rises on strong Asceniv demand and boosted 2025-2026 guidance. However, valuation warrants investor caution.
GRFSNegative Net Change ADMANo Net Change TAKNegative Net Change
biotechnology biotechs medical pharmaceuticals
BMY Collaborates for Oncology Drug: Will This Boost Its Portfolio?
by Ekta Bagri
BMY teams with BioNTech on BNT327, a dual-target cancer therapy, as legacy drugs face mounting generic pressure
BMYNegative Net Change PFENegative Net Change MRKNegative Net Change BNTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can New Cancer Drug Emrelis Drive AbbVie's Oncology Franchise?
by Sundeep Ganoria
Emrelis wins FDA approval, marking ABBV's first lung cancer drug and strengthening its oncology reach into solid tumors.
REGNNegative Net Change AZNNegative Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
Zoetis Stock Rises 13% in a Month: Time to Add to Your Portfolio?
by Zacks Equity Research
ZTS jumps 13% in a month as strong new product sales, strategic deals, and rising earnings estimates boost investor confidence.
BAYRYNegative Net Change LXRXPositive Net Change AMRNPositive Net Change ZTSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success
by Zacks Equity Research
LYRA skyrockets 356% after its lead nasal implant, LYR-210, meets key goals in a pivotal phase III chronic rhinosinusitis study.
BAYRYNegative Net Change LXRXPositive Net Change AMRNPositive Net Change LYRANegative Net Change
biotechnology biotechs medical pharmaceuticals
FDA Grants Platform Technology Tag to Sarepta's Gene Therapy Vector
by Zacks Equity Research
With FDA platform technology designation for its viral vector, SRPT can fast-track other therapies using the same gene-delivery method.
RHHBYNegative Net Change SRPTNegative Net Change AGENNegative Net Change IMCRNegative Net Change
biotechs gene-editing gene-therapy medical pharmaceuticals
REGN Strengthens Obesity Pipeline: Will the Move Revive the Stock?
by Zacks Equity Research
REGN inks a $2B-plus obesity drug deal with Hansoh, aiming to expand its pipeline amid slumping Eylea sales and pipeline setbacks.
REGNNegative Net Change SNYNegative Net Change NVOPositive Net Change LLYNegative Net Change
biotechnology biotechs medical pharmaceuticals